TY - JOUR
T1 - Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins
AU - Matešić, Marina Pribanić
AU - Brlić, Paola Kučan
AU - Roviš, Tihana Lenac
AU - Šafranko, Željka Mačak
AU - Chaouat, Abigael Eva
AU - Miklić, Karmela
AU - Malić, Suzana
AU - Ivanković, Nina
AU - Schubert, Maren
AU - Bertoglio, Federico
AU - Markotić, Alemka
AU - Mandelboim, Ofer
AU - Jonjić, Stipan
AU - Brizić, Ilija
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/21
Y1 - 2022/2/21
N2 - In early 2020, the COVID-19 pandemic sparked a global crisis that continues to pose a serious threat to human health and the economy. Further advancement in research is necessary and requires the availability of quality molecular tools, including monoclonal antibodies. Here, we present the development and characterization of a collection of over 40 new monoclonal antibodies directed against different SARS-CoV-2 proteins. Recombinant SARS-CoV-2 proteins were expressed, purified, and used as immunogens. Upon development of specific hybridomas, the obtained monoclonal antibody (mAb) clones were tested for binding to recombinant proteins and infected cells. We gener-ated mAbs against structural proteins, the Spike and Nucleocapsid protein, several non-structural proteins (nsp1, nsp7, nsp8, nsp9, nsp10, nsp16) and accessory factors (ORF3a, ORF9b) applicable in flow cytometry, immunofluorescence, or Western blot. Our collection of mAbs provides a set of novel, highly specific tools that will allow a comprehensive analysis of the viral proteome, which will allow further understanding of SARS-CoV-2 pathogenesis and the design of therapeutic strategies.
AB - In early 2020, the COVID-19 pandemic sparked a global crisis that continues to pose a serious threat to human health and the economy. Further advancement in research is necessary and requires the availability of quality molecular tools, including monoclonal antibodies. Here, we present the development and characterization of a collection of over 40 new monoclonal antibodies directed against different SARS-CoV-2 proteins. Recombinant SARS-CoV-2 proteins were expressed, purified, and used as immunogens. Upon development of specific hybridomas, the obtained monoclonal antibody (mAb) clones were tested for binding to recombinant proteins and infected cells. We gener-ated mAbs against structural proteins, the Spike and Nucleocapsid protein, several non-structural proteins (nsp1, nsp7, nsp8, nsp9, nsp10, nsp16) and accessory factors (ORF3a, ORF9b) applicable in flow cytometry, immunofluorescence, or Western blot. Our collection of mAbs provides a set of novel, highly specific tools that will allow a comprehensive analysis of the viral proteome, which will allow further understanding of SARS-CoV-2 pathogenesis and the design of therapeutic strategies.
KW - COVID-19
KW - Monoclonal antibodies
KW - SARS-CoV-2
KW - Variants of concern
UR - http://www.scopus.com/inward/record.url?scp=85125177239&partnerID=8YFLogxK
U2 - 10.3390/v14020443
DO - 10.3390/v14020443
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35216036
AN - SCOPUS:85125177239
SN - 1999-4915
VL - 14
JO - Viruses
JF - Viruses
IS - 2
M1 - 443
ER -
